At the next CTAD conference (Boston, 1-4 November) results of two phases III studies will be presented. A treatment with beta secretase inhibitors and a symptomatic treatment. Furthermore many results of several phase II studies will be featured at the event including the new anti-tau. After many years of negative results, it seems that we are making significant advances in the treatment of Alzheimer’s disease. Some of these presentations will be available online: program